Latest Breaking News On - Minnesota consortium for autonomic neuromodulation - Page 1 : comparemela.com

BioSig Technologies : Annual report pursuant to Section 13 and 15(d)

Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended. | March 31, 2023

University of Minnesota awarded $21M to lead research revealing effects of vagus nerve stimulation in humans

Mega effort to study vagus nerve stimulation

University of Minnesota awarded $21M to lead research

Interdisciplinary team brings together 8 institutions across the globe for a first-of-a-kind study.

BioSig's Division NeuroClear Technologies Signs a Research Agreement with the University of MinnesotaNeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease

Published: Dec 18, 2020 Westport, CT, Dec. 18, 2020 (GLOBE NEWSWIRE) BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company and its NeuroClear Technologies division signed a new research agreement with the University of Minnesota.  Under the terms of the agreement, the Company intends to launch a program to develop novel therapies to treat sympathetic nervous system disease. Due to launch in Q4 2020, the program studies are expected to form a foundation for developing a new platform technology to address disorders of the autonomic nervous system. NeuroClear intends to develop new intellectual properties and products, including new hardware, software, and algorithmic solutions, with the support of a tier 1 US-based manufacturing